Lonza Group Ltd (OTCMKTS:LZAGY) Receives Average Rating of “Buy” from Analysts

Lonza Group Ltd (OTCMKTS:LZAGY) has been given an average rating of “Buy” by the eleven analysts that are covering the stock, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company.

LZAGY has been the subject of several research reports. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Lonza Group in a research note on Tuesday, February 16th. JPMorgan Chase & Co. upgraded Lonza Group from a “neutral” rating to an “overweight” rating in a research note on Tuesday, February 23rd. The Goldman Sachs Group upgraded Lonza Group from a “neutral” rating to a “buy” rating in a research note on Tuesday. William Blair reiterated an “outperform” rating on shares of Lonza Group in a research note on Thursday, February 11th. Finally, Morgan Stanley reiterated an “overweight” rating on shares of Lonza Group in a research note on Tuesday, May 11th.

Shares of LZAGY traded up $1.23 during trading hours on Friday, hitting $73.09. The stock had a trading volume of 39,398 shares, compared to its average volume of 88,061. The business’s 50 day moving average is $62.59. The firm has a market cap of $54.43 billion, a price-to-earnings ratio of 56.22 and a beta of 0.63. Lonza Group has a 1-year low of $48.40 and a 1-year high of $73.11.

The company also recently announced an annual dividend, which was paid on Thursday, May 27th. Shareholders of record on Tuesday, May 11th were given a dividend of $0.094 per share. The ex-dividend date was Monday, May 10th. This represents a dividend yield of 0.15%. Lonza Group’s dividend payout ratio is currently 6.92%.

About Lonza Group

Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. The company operates through two segments, Pharma Biotech & Nutrition, and Specialty Ingredients. The Pharma Biotech & Nutrition segment provides technology platforms, including drug substance and drug product; and develops and manufactures customized active pharmaceutical ingredients and biopharmaceuticals, as well as formulation services and delivery systems for pharmaceutical and nutritional applications.

Featured Article: Back-End Load

Analyst Recommendations for Lonza Group (OTCMKTS:LZAGY)

Receive News & Ratings for Lonza Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lonza Group and related companies with MarketBeat.com's FREE daily email newsletter.